NPRL2 and hepatocellular carcinoma: Reduced expression or deletion of NPRL2 was found in many cancers including lung, renal, colorectal, glioma, gastric, and hepatocellular carcinoma, and has been closely correlated with poor clinical outcomes (Liu et al., 2014; Pi et al., 2022; Huang et al., 2016; Tang et al., 2014; Otani et al., 2009; Senchenko et al., 2010; Zabarovsky et al., 2002).